Trial Profile
A phase I study for safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of KL130008 capsules in healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs KL-130008 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Sichuan Kelun-Biotech Biopharmaceutical
- 03 Aug 2022 Status changed from not yet recruiting to completed as per results published in the European Journal of Pharmaceutical Sciences
- 03 Aug 2022 Results published in the European Journal of Pharmaceutical Sciences
- 22 Jun 2020 Status changed from recruiting to not yet recruiting.